In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni raise substantial new funding, receive Breakthrough Device Designation, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Launched its second fund, 415 Capital Fund II, with a target of €150M. The funds will drive the development of breakthrough technologies, with a focus on innovations targeting cardiovascular and neurovascular diseases.
Entered a collaboration with the Mayo Clinic. Through this collaboration, Biomendex will leverage input from select Mayo Clinic surgeons to develop its synthetic bone graft technology, AdaptosⓇ, for new healthcare segments.
Presented positive six-month data from its Valvosoft Pivotal Study. Its Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device met the primary endpoint and improved or stabilized heart failure symptoms for 80.5% of patients.
Received De Novo approval from the FDA to market its DexterⓇ Surgical Robot for adult inguinal hernia repair. The company’s technology aims to overcome challenges relating to cost, space limitations, and workflow disruption.
Closed a $50M Series B funding round led by imec.xpand. The funds will help the company accelerate the development of its graphene-based BCI platform, which offers a bidirectional solution for decoding and modulating neural activity.
Received FDA Breakthrough Device Designation for its NIOⓇ Lung Cancer Reveal image analysis module. It is intended to support physicians in evaluating bronchoscopic lung forceps biopsies.
Successfully closed a €750k funding round with SWEN Capital Partners. The funding will help the company accelerate the development of its 3D imaging platform designed to improve precision in diagnosing and treating heart rhythm disorders.
Raised a $28.5M Series B funding round led by RA Capital Management. The company’s device, Trillium™, is designed to treat tricuspid regurgitation through a heterotopic, cross-caval approach, leaving the native valve untouched.
Announced promising new clinical data from the BIPASS-AKI Feasibility Study of its JuxtaFlowⓇ Renal Assist Device (RAD). The device aims to sustain or enhance kidney function in patients with pre-existing renal impairment undergoing cardiac surgery with cardiopulmonary bypass.
Raised £3.8m in a funding round led by Mercia Ventures to scale its global operations. The company combines machine learning and computer vision to identify and track surgical trays, instruments, and implants.
Announced the results of a 52-week Phase 2 Study in Mild-to-Moderate Alzheimer’s disease patients. The company’s personalized, closed-loop neuromodulation therapy met the primary and key secondary endpoints.
Appointed Deborah Kilpatrick, Ph.D as a Venture Partner. Kilpatrick, former CEO of Evidation Health and Co-Founder of MedtechWomen, will play a key role in helping the company identify future investments in the medtech market.
Achieved ISO 13485 certification. Stimdia develops the pdSTIM™ System, which aims to awaken and recondition the diaphragm in patients on mechanical ventilation to support independent breathing.
Announced initial positive results from its IDE PATCH Pivotal Study of its Vivasure PerQsealⓇ Closure Device System. PerQseal is a fully absorbable, patch-based closure device designed to seal large-bore arteriotomies in endovascular procedures.
Appointed Brandon Rowberry as Chief Digital Officer & Managing Director of its worldwide digital platforms. Xenter is developing a wireless “Technology in Medicine” ecosystem intended to improve outcomes for patients.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
